A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis

Robert Zivadinov, Michael Dwyer, Silva Markovic-Plese, Brooke Hayward, Niels Bergsland, Mari Heininen-Brown, Ellen Carl, Cheryl Kennedy, Fernando Dangond, Bianca Weinstock-Guttman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Studies have shown a relationship between increased iron content and clinical progression, cognitive impairment, and brain atrophy in patients with multiple sclerosis. Altered phase, as determined by susceptibility-weighted imaging (SWI), can potentially capture iron content changes. Objective: The objective of this study was to investigate phase changes in white matter (WM) lesions and subcortical deep-gray matter (SDGM) of patients with relapsing-remitting (RR) MS treated with interferon beta-1a administered subcutaneously versus untreated healthy controls (HCs). Methods: We conducted a 24-week, nonrandomized, open-label pilot study of 23 patients with RRMS receiving interferon beta-1a administered subcutaneously and 15 HCs. Patients were imaged on a 3T scanner at baseline, 12, and 24 weeks; changes in phase behavior in WM lesions and regional SDGM [mean phase of low-phase voxels (MP-LPV)], and in SDGM volumes, were measured. Between- and within-group changes were tested using nonparametric statistics adjusted for multiple comparisons. Results: The number (p = 0.003) and volume (p <0.001) of phase WM lesions both significantly decreased among RRMS patients over 24 weeks. At baseline, MP-LPV was lower (suggestive of greater iron content) in total SDGM among RRMS patients versus HCs (p = 0.002). Week 24 MP-LPV changes from baseline were not significantly different between groups in total SDGM or any region except the putamen (-0.0025 radians in RRMS patients versus 0.0035 radians in HCs; p = 0.041). Conclusions: Over 24 weeks, phase lesions were reduced significantly in the RRMS group. These preliminary results suggest that SWI-filtered phase may become a useful tool for monitoring RRMS disease activity.

Original languageEnglish
Pages (from-to)59-70
Number of pages12
JournalTherapeutic Advances in Neurological Disorders
Volume8
Issue number2
DOIs
Publication statusPublished - Mar 15 2015

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Iron
Putamen
Nonparametric Statistics
Gray Matter
Interferon beta-1a
Multiple Sclerosis
Atrophy
Brain

Keywords

  • iron
  • MRI
  • multiple sclerosis
  • phase assessment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pharmacology

Cite this

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. / Zivadinov, Robert; Dwyer, Michael; Markovic-Plese, Silva; Hayward, Brooke; Bergsland, Niels; Heininen-Brown, Mari; Carl, Ellen; Kennedy, Cheryl; Dangond, Fernando; Weinstock-Guttman, Bianca.

In: Therapeutic Advances in Neurological Disorders, Vol. 8, No. 2, 15.03.2015, p. 59-70.

Research output: Contribution to journalArticle

Zivadinov, Robert ; Dwyer, Michael ; Markovic-Plese, Silva ; Hayward, Brooke ; Bergsland, Niels ; Heininen-Brown, Mari ; Carl, Ellen ; Kennedy, Cheryl ; Dangond, Fernando ; Weinstock-Guttman, Bianca. / A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. In: Therapeutic Advances in Neurological Disorders. 2015 ; Vol. 8, No. 2. pp. 59-70.
@article{9a9907ecd426487e8a21f1800e3fc77d,
title = "A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis",
abstract = "Background: Studies have shown a relationship between increased iron content and clinical progression, cognitive impairment, and brain atrophy in patients with multiple sclerosis. Altered phase, as determined by susceptibility-weighted imaging (SWI), can potentially capture iron content changes. Objective: The objective of this study was to investigate phase changes in white matter (WM) lesions and subcortical deep-gray matter (SDGM) of patients with relapsing-remitting (RR) MS treated with interferon beta-1a administered subcutaneously versus untreated healthy controls (HCs). Methods: We conducted a 24-week, nonrandomized, open-label pilot study of 23 patients with RRMS receiving interferon beta-1a administered subcutaneously and 15 HCs. Patients were imaged on a 3T scanner at baseline, 12, and 24 weeks; changes in phase behavior in WM lesions and regional SDGM [mean phase of low-phase voxels (MP-LPV)], and in SDGM volumes, were measured. Between- and within-group changes were tested using nonparametric statistics adjusted for multiple comparisons. Results: The number (p = 0.003) and volume (p <0.001) of phase WM lesions both significantly decreased among RRMS patients over 24 weeks. At baseline, MP-LPV was lower (suggestive of greater iron content) in total SDGM among RRMS patients versus HCs (p = 0.002). Week 24 MP-LPV changes from baseline were not significantly different between groups in total SDGM or any region except the putamen (-0.0025 radians in RRMS patients versus 0.0035 radians in HCs; p = 0.041). Conclusions: Over 24 weeks, phase lesions were reduced significantly in the RRMS group. These preliminary results suggest that SWI-filtered phase may become a useful tool for monitoring RRMS disease activity.",
keywords = "iron, MRI, multiple sclerosis, phase assessment",
author = "Robert Zivadinov and Michael Dwyer and Silva Markovic-Plese and Brooke Hayward and Niels Bergsland and Mari Heininen-Brown and Ellen Carl and Cheryl Kennedy and Fernando Dangond and Bianca Weinstock-Guttman",
year = "2015",
month = "3",
day = "15",
doi = "10.1177/1756285615572953",
language = "English",
volume = "8",
pages = "59--70",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis

AU - Zivadinov, Robert

AU - Dwyer, Michael

AU - Markovic-Plese, Silva

AU - Hayward, Brooke

AU - Bergsland, Niels

AU - Heininen-Brown, Mari

AU - Carl, Ellen

AU - Kennedy, Cheryl

AU - Dangond, Fernando

AU - Weinstock-Guttman, Bianca

PY - 2015/3/15

Y1 - 2015/3/15

N2 - Background: Studies have shown a relationship between increased iron content and clinical progression, cognitive impairment, and brain atrophy in patients with multiple sclerosis. Altered phase, as determined by susceptibility-weighted imaging (SWI), can potentially capture iron content changes. Objective: The objective of this study was to investigate phase changes in white matter (WM) lesions and subcortical deep-gray matter (SDGM) of patients with relapsing-remitting (RR) MS treated with interferon beta-1a administered subcutaneously versus untreated healthy controls (HCs). Methods: We conducted a 24-week, nonrandomized, open-label pilot study of 23 patients with RRMS receiving interferon beta-1a administered subcutaneously and 15 HCs. Patients were imaged on a 3T scanner at baseline, 12, and 24 weeks; changes in phase behavior in WM lesions and regional SDGM [mean phase of low-phase voxels (MP-LPV)], and in SDGM volumes, were measured. Between- and within-group changes were tested using nonparametric statistics adjusted for multiple comparisons. Results: The number (p = 0.003) and volume (p <0.001) of phase WM lesions both significantly decreased among RRMS patients over 24 weeks. At baseline, MP-LPV was lower (suggestive of greater iron content) in total SDGM among RRMS patients versus HCs (p = 0.002). Week 24 MP-LPV changes from baseline were not significantly different between groups in total SDGM or any region except the putamen (-0.0025 radians in RRMS patients versus 0.0035 radians in HCs; p = 0.041). Conclusions: Over 24 weeks, phase lesions were reduced significantly in the RRMS group. These preliminary results suggest that SWI-filtered phase may become a useful tool for monitoring RRMS disease activity.

AB - Background: Studies have shown a relationship between increased iron content and clinical progression, cognitive impairment, and brain atrophy in patients with multiple sclerosis. Altered phase, as determined by susceptibility-weighted imaging (SWI), can potentially capture iron content changes. Objective: The objective of this study was to investigate phase changes in white matter (WM) lesions and subcortical deep-gray matter (SDGM) of patients with relapsing-remitting (RR) MS treated with interferon beta-1a administered subcutaneously versus untreated healthy controls (HCs). Methods: We conducted a 24-week, nonrandomized, open-label pilot study of 23 patients with RRMS receiving interferon beta-1a administered subcutaneously and 15 HCs. Patients were imaged on a 3T scanner at baseline, 12, and 24 weeks; changes in phase behavior in WM lesions and regional SDGM [mean phase of low-phase voxels (MP-LPV)], and in SDGM volumes, were measured. Between- and within-group changes were tested using nonparametric statistics adjusted for multiple comparisons. Results: The number (p = 0.003) and volume (p <0.001) of phase WM lesions both significantly decreased among RRMS patients over 24 weeks. At baseline, MP-LPV was lower (suggestive of greater iron content) in total SDGM among RRMS patients versus HCs (p = 0.002). Week 24 MP-LPV changes from baseline were not significantly different between groups in total SDGM or any region except the putamen (-0.0025 radians in RRMS patients versus 0.0035 radians in HCs; p = 0.041). Conclusions: Over 24 weeks, phase lesions were reduced significantly in the RRMS group. These preliminary results suggest that SWI-filtered phase may become a useful tool for monitoring RRMS disease activity.

KW - iron

KW - MRI

KW - multiple sclerosis

KW - phase assessment

UR - http://www.scopus.com/inward/record.url?scp=84924861630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924861630&partnerID=8YFLogxK

U2 - 10.1177/1756285615572953

DO - 10.1177/1756285615572953

M3 - Article

AN - SCOPUS:84924861630

VL - 8

SP - 59

EP - 70

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

IS - 2

ER -